All In Biotech

Drug Trial Radar · NCT03122262

ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy

WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 Weeks

Last checked: Nov 19, 2026Latest source record: Feb 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,110

Actual

Start

Jan 16, 2017

Primary completion

Apr 30, 2022

Study completion Jul 29, 2022

Sponsor

Lead sponsor
Professor Francois VenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a non-inferiority (10% non-inferiority margin), study to assess the efficacy and safety of dolutegravir, DTG (50 mg once daily \[QD\]) administered in combination with tenofovir alafenamide fumarate, TAF (25 mg QD) and emtricitabine, FTC (200 mg QD) compared to DTG (50 mg QD) administered in combination with tenofovir disoproxil fumarate, TDF (300 mg QD) and FTC (200 mg QD) and compared to efavirenz, EFV (600 mg QD) administered in combination with TDF (300 mg QD) and FTC (200 mg QD) through 96 weeks in patients with HIV-1 starting first-line ART.

Conditions

  • HIV-1 Infection

Interventions

  • DolutegravirDrug

    DTG 50mg Oral Tablet once daily

  • Tenofovir AlafenamideDrug

    TAF/FTC 25/200mg Oral Tablet once daily

  • TruvadaDrug

  • AtriplaDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with undetectable plasma HIV-1 RNA levels (< 50 copies/mL) at Week 48Time frame: 48 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Shandukani Research Centre

    Johannesburg, Gauteng, South Africa

  • Charlotte Maxeke Johannesburg Academic Hospital

    Johannesburg, Gauteng, South Africa

  • Sunnyside Office Park

    Johannesburg, Gauteng, South Africa

  • Wits RHI Yeoville Clinic

    Johannesburg, Gauteng, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.